Last March, Ziopharm Oncology executives said they walked out of an FDA meeting with “positive guidance” on the design of a Phase 3 clinical trial for its experimental IL-12 gene therapy in patients with glioblastoma, the type of aggressive brain cancer afflicting U.S. Sen. John McCain.

Four months later, Ziopharm still hasn’t offered investors any specific details about that “successful” FDA meeting, or a similar meeting held with European regulators.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy